Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease

Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news